

Pierre Deharo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/435690/publications.pdf>

Version: 2024-02-01

53
papers

1,036
citations

516710

16
h-index

454955

30
g-index

55
all docs

55
docs citations

55
times ranked

1625
citing authors

#	ARTICLE	IF	CITATIONS
1	Myocardial Revascularization Strategies in ST Elevation Myocardial Infarction Without Urgent Revascularization: Insight From a Nationwide Study. <i>Mayo Clinic Proceedings</i> , 2022, , .	3.0	0
2	Valve-in-valve transcatheter aortic valve implantation after failed surgically implanted aortic bioprosthesis versus native transcatheter aortic valve implantation for aortic stenosis: Data from a nationwide analysis. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 41-50.	1.6	6
3	Re-intervention for failed surgical aortic bioprosthesis: Remaining questions on long term outcomes and selection of patients. <i>International Journal of Cardiology</i> , 2021, 323, 242.	1.7	0
4	Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1690.	4.1	42
5	Rapid deployment versus transcatheter aortic valve replacement in intermediate-risk patients: A propensity score analysis. <i>Journal of Cardiac Surgery</i> , 2021, 36, 2004-2012.	0.7	7
6	EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020): Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology.. <i>EuroIntervention</i> , 2021, 17, 23-31.	3.2	4
7	Outcomes associated with pacemaker implantation following transcatheter aortic valve replacement: A nationwide cohort study. <i>Heart Rhythm</i> , 2021, 18, 2027-2032.	0.7	9
8	Prosthesis-patient mismatch is an independent predictor of congestive heart failure after transcatheter aortic valve replacement. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 504-514.	1.6	4
9	Adenosine Receptor Reserve and Long-Term Potentiation: Unconventional Adaptive Mechanisms in Cardiovascular Diseases?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7584.	4.1	5
10	De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 763-777.	2.8	42
11	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. <i>Atherosclerosis</i> , 2021, 332, 48-54.	0.8	28
12	Outcomes Following Aortic Stenosis Treatment (Transcatheter vs Surgical Replacement) in Women vs Men (From a Nationwide Analysis). <i>American Journal of Cardiology</i> , 2021, 154, 67-77.	1.6	2
13	Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 198-202.	4.9	4
14	Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis. <i>Circulation</i> , 2020, 141, 260-268.	1.6	104
15	Rotational atherectomy through a coronary artery bypass graft after transcatheter aortic valve implantation: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-5.	0.6	1
16	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2020, 396, 1737-1744.	13.7	75
17	Adenosine and Its Receptors: An Expected Tool for the Diagnosis and Treatment of Coronary Artery and Ischemic Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5321.	4.1	17
18	Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 489-499.	2.8	93

#	ARTICLE	IF	CITATIONS
19	Reply. Journal of the American College of Cardiology, 2020, 76, 2287.	2.8	0
20	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. Journal of the American College of Cardiology, 2020, 76, 2321-2330.	2.8	154
21	Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis. Journal of the American Heart Association, 2020, 9, e015896.	3.7	30
22	Futility Risk Model for Predicting Outcome After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 130, 100-107.	1.6	16
23	Response by Deharo et al to Letter Regarding Article, "Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis". Circulation, 2020, 141, e912-e913.	1.6	1
24	Transcatheter aortic valve replacement using the ACURATE NEO™ valve to treat pure aortic regurgitation in a degenerated aortic homograft valve. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	0
25	Homocysteine concentration and adenosine A _{2A} receptor production by peripheral blood mononuclear cells in coronary artery disease patients. Journal of Cellular and Molecular Medicine, 2020, 24, 8942-8949.	3.6	4
26	Outcomes in nonagenarians undergoing transcatheter aortic valve implantation: a nationwide analysis. EuroIntervention, 2020, 15, 1489-1496.	3.2	12
27	Platelet CD 40 ligand and bleeding during P2Y ₁₂ inhibitor treatment in acute coronary syndrome. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 684-694.	2.3	4
28	Pharmacological profile of adenosine A _{2A} receptors in patients with lower extremity peripheral artery disease and associated coronary artery disease: A pilot study. International Journal of Cardiology, 2019, 285, 121-127.	1.7	13
29	Adenosine plasma level in patients with paroxysmal or persistent atrial fibrillation and normal heart during ablation procedure and/or cardioversion. Purinergic Signalling, 2019, 15, 45-52.	2.2	17
30	Hepatitis E virus infection in heart transplant recipients, Southeastern France. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 108-111.	1.5	5
31	Reply. JACC: Cardiovascular Interventions, 2018, 11, 508-509.	2.9	0
32	Monitoring platelet function: what have we learned from randomized clinical trials?. Cardiovascular Diagnosis and Therapy, 2018, 8, 621-629.	1.7	5
33	Impact of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty on Procedural and Clinical Outcomes. JACC: Cardiovascular Interventions, 2018, 11, 1956-1965.	2.9	42
34	Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis. Open Heart, 2018, 5, e000767.	2.3	3
35	Transcatheter valve-in-valve implantation in a degenerated very small Mitroflow prosthesis. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 850-855.	1.1	6
36	Primary percutaneous coronary intervention of native chronic total occlusions to treat ST elevation myocardial infarction secondary to acute vein graft occlusion. Catheterization and Cardiovascular Interventions, 2017, 90, 251-256.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Timing of Angiography and Outcomes in High-Risk Patients With Non-“ST-Segment” Elevation Myocardial Infarction Managed Invasively. <i>Circulation</i> , 2017, 136, 1895-1907.	1.6	29
38	The role of optical coherence tomography in decision making during the acute phase of spontaneous coronary artery dissection. <i>IJC Heart and Vasculature</i> , 2017, 14, 6-7.	1.1	7
39	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2560-2570.	2.9	36
40	Bail-Out Alcohol Septal Ablation for Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, e73-e76.	2.9	30
41	High homocysteine levels prevent <i>in vitro</i> H ₂ O ₂ the CoCl ₂ -induced alteration of lymphocyte viability. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1411-1419.	3.6	11
42	Is platelet inhibition correlated with time from last intake on P2Y ₁₂ blockers after an acute coronary syndrome? A pilot study. <i>Platelets</i> , 2016, 27, 791-795.	2.3	1
43	Optimizing adjunctive antithrombotic and anticoagulant therapy in primary PCI for STEMI. <i>Minerva Cardioangiologica</i> , 2016, 64, 238-55.	1.2	0
44	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y ₁₂ inhibitors. <i>International Journal of Cardiology</i> , 2015, 184, 428-430.	1.7	7
45	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. <i>Annales De Cardiologie Et D'Angiologie</i> , 2014, 63, 222-227.	0.6	7
46	Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 172, e1-e2.	1.7	13
47	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. <i>American Journal of Cardiology</i> , 2014, 113, 54-59.	1.6	35
48	Effectiveness of switching “low responders” to prasugrel to ticagrelor after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 176, 1184-1185.	1.7	10
49	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. <i>International Journal of Cardiology</i> , 2014, 176, 1200-1202.	1.7	21
50	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. <i>International Journal of Cardiology</i> , 2013, 170, e21-e22.	1.7	24
51	Effectiveness of switching “hyper responders” from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. <i>International Journal of Cardiology</i> , 2013, 168, 5004-5005.	1.7	15
52	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 2988-2989.	1.7	7
53	Exercise-induced acute coronary syndrome in a 24-year-old man with massive cannabis consumption. <i>Acta Cardiologica</i> , 2013, 68, 425-428.	0.9	20